rs63750126
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_000251.3(MSH2):c.482T>A(p.Val161Asp) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★).
Frequency
Genomes: not found (cov: 31)
Consequence
MSH2
NM_000251.3 missense
NM_000251.3 missense
Scores
15
2
2
Clinical Significance
Conservation
PhyloP100: 7.93
Genes affected
MSH2 (HGNC:7325): (mutS homolog 2) This locus is frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). When cloned, it was discovered to be a human homolog of the E. coli mismatch repair gene mutS, consistent with the characteristic alterations in microsatellite sequences (RER+ phenotype) found in HNPCC. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PM1
In a strand (size 7) in uniprot entity MSH2_HUMAN there are 9 pathogenic changes around while only 2 benign (82%) in NM_000251.3
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.983
PP5
Variant 2-47410209-T-A is Pathogenic according to our data. Variant chr2-47410209-T-A is described in ClinVar as [Pathogenic]. Clinvar id is 91104.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47410209-T-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MSH2 | NM_000251.3 | c.482T>A | p.Val161Asp | missense_variant | 3/16 | ENST00000233146.7 | NP_000242.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MSH2 | ENST00000233146.7 | c.482T>A | p.Val161Asp | missense_variant | 3/16 | 1 | NM_000251.3 | ENSP00000233146 | P1 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD3 genomes
Cov.:
31
GnomAD4 exome Cov.: 32
GnomAD4 exome
Cov.:
32
GnomAD4 genome Cov.: 31
GnomAD4 genome
Cov.:
31
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:3
Revision: reviewed by expert panel
LINK: link
Submissions by phenotype
Lynch syndrome 1 Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Jul 27, 2023 | This variant is considered likely pathogenic. This variant is expected to disrupt protein structure [Myriad internal data]. Functional studies indicate this variant impacts protein function [PMID: 17101317, 26951660]. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 15849733, 28785832]. - |
Pathogenic, reviewed by expert panel | curation | International Society for Gastrointestinal Hereditary Tumours (InSiGHT) | Mar 09, 2018 | Class 5 - Pathogenic Classification using multifactorial probability: 0.9977 - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 13, 2023 | The p.V161D pathogenic mutation (also known as c.482T>A), located in coding exon 3 of the MSH2 gene, results from a T to A substitution at nucleotide position 482. The valine at codon 161 is replaced by aspartic acid, an amino acid with highly dissimilar properties. In one study, this variant was detected in an individual diagnosed with colorectal cancer at 52 years of age who met Amsterdam I criteria for Lynch syndrome and tumor demonstrated high microsatellite instability (MSI-H) with negative staining for MSH2 on immunohistochemistry (IHC). An in vitro MMR assay revealed that this variant protein was completely deficient in MMR activity (Ollila S et al. Gastroenterology 2006 Nov; 131(5):1408-17). This alteration was also reported by an Italian group in a family that met Amsterdam II criteria for Lynch syndrome and the alteration segregated in three affected family members. The proband and her mother had Lynch-associated tumors that demonstrated MSI-H and absent MSH2/MSH6 staining on IHC. Furthermore, the MSH2 V161D protein showed an abnormal subcellular localization pattern compared to wild type MSH2 protein (Bianchi F et al. Fam. Cancer, 2018 Apr;17:215-224). In another study, the MSH2 V161D protein showed deficient mismatch repair activity using a genetic screen in mouse embryonic stem cells, reduced protein expression, and increased microsatellite instability compared to wild type MSH2 protein (Houlleberghs H et al. Proc. Natl. Acad. Sci. U.S.A., 2016 Apr;113:4128-33). In a massively parallel cell-based functional assay testing susceptibility to a DNA damaging agent, 6-thioguanine (6-TG), this variant was reported to be functionally deleterious (Jia X et al. Am J Hum Genet, 2021 Jan;108:163-175). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
D;D;.;.;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
M;.;.;.;.
MutationTaster
Benign
D;D;D
PrimateAI
Benign
T
PROVEAN
Pathogenic
D;D;D;.;D
REVEL
Pathogenic
Sift
Pathogenic
D;D;D;.;D
Sift4G
Pathogenic
D;D;D;.;D
Polyphen
D;.;.;.;D
Vest4
MutPred
Gain of disorder (P = 0.0098);.;.;Gain of disorder (P = 0.0098);Gain of disorder (P = 0.0098);
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at